EFFICACY OF SULPHASALAZINE ON LUNG HISTOPATHOLOGY IN A MURINE MODEL OF CHRONIC ASTHMA

被引:24
作者
Olmez, Duygu [1 ]
Babayigit, Arzu [1 ]
Uzuner, Nevin [1 ]
Erbil, Guven [2 ]
Karaman, Ozkan [3 ]
Yilmaz, Osman [4 ]
Cetin, Emel Oyku [5 ]
Ozogul, Candan [2 ]
机构
[1] Dokuz Eylul Univ Hosp, Dept Pediat Allergy, Izmir, Turkey
[2] Dokuz Eylul Univ Hosp, Dept Histol & Embryol, Izmir, Turkey
[3] Dokuz Eylul Univ Hosp, Dept Pediat Allergy, Izmir, Turkey
[4] Dokuz Eylul Univ Hosp, Dept Expt Anim Lab, Izmir, Turkey
[5] Ege Univ, Fac Pharm, Dept Biopharmaceut & Pharmacokinet, Izmir, Turkey
关键词
chronic asthma; mice; sulphasalazine; treatment;
D O I
10.1080/01902140802271859
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Sulphasalazine is a specific inhibitor of nuclear factor kappa B (NF-kappa B) which plays a key role in asthma. To determine the impact of sulphasalazine in. the treatment of chronic asthma, BALB/c mice were sensitized and challenged with ovalbumin. Mice With experimentally induced asthma in group I received saline, group II sulphasalazine 200 mg/kg, group III sulphasalazine 300 mg/kg, and group IV dexamethasone 1 mg/kg intraperitoneally once a day in the last 7 days of the challenge period. Histological findings of the airways were evaluated by light and electron microscopies. Dexamethasone and sulphasalazine in both doses significantly improved all airway histopathologic parameters of asthma except numbers of goblet cells. Both doses of sulphasalazine improved thicknesses of basement membrane better than dexamethasone. Dexamethasone reduced the number of mast cells better than sulphasalazine (200 mg/kg). Further studies are needed to evaluate the efficacy of sulphasalazine in the treatment of asthma.
引用
收藏
页码:501 / 511
页数:11
相关论文
共 44 条
[1]
INHIBITION OF CELL-MEDIATED CYTOTOXICITY BY SULFASALAZINE - EFFECT OF INVIVO TREATMENT WITH 5-AMINOSALICYLIC ACID AND SULFASALAZINE ON INVITRO NATURAL-KILLER-CELL ACTIVITY [J].
APARICIOPAGES, MN ;
VERSPAGET, HW ;
HAFKENSCHEID, JCM ;
CRAMABOHBOUTH, GE ;
PENA, AS ;
WETERMAN, IT ;
LAMERS, CBHW .
GUT, 1990, 31 (09) :1030-1032
[2]
Transcription factors in airway diseases [J].
Barnes, Peter J. .
LABORATORY INVESTIGATION, 2006, 86 (09) :867-872
[3]
Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases [J].
Barnes, PJ ;
Larin, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) :1066-1071
[4]
Aspirin and decreased adult-onset asthma - Randomized comparisons from the Physicians' Health Study [J].
Barr, R. Graham ;
Kurth, Tobias ;
Stampfer, Meir J. ;
Buring, Julie E. ;
Hennekens, Charles H. ;
Gaziano, J. Michael .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 175 (02) :120-125
[5]
Bissonnette EY, 1996, J IMMUNOL, V156, P218
[6]
Specificity of basement membrane thickening in severe asthma [J].
Bourdin, Arnaud ;
Neveu, Dorine ;
Vachier, Isabelle ;
Paganin, Fabrice ;
Godard, Philippe ;
Chanez, Pascal .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (06) :1367-1374
[7]
Advances in immunology - Asthma [J].
Busse, WW ;
Lemanske, RF .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (05) :350-362
[8]
Salicylate-enhanced activation of transcription factors induced by interferon-γ [J].
Chen, LC ;
Kepka-Lenhart, D ;
Wright, TM ;
Morris, SM .
BIOCHEMICAL JOURNAL, 1999, 342 :503-507
[9]
Anti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX [J].
Chiang, N ;
Arita, M ;
Serhan, CN .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2005, 73 (3-4) :163-177
[10]
The role of nuclear factor-κ B in pulmonary diseases [J].
Christman, JW ;
Sadikot, RT ;
Blackwell, TS .
CHEST, 2000, 117 (05) :1482-1487